|
Forest Gets Untitled Letter After Reps Downplay Weight-Loss Risks
Forest Laboratories has been hit with an untitled letter after two of its sales reps implied that weight loss while using Daliresp tablets — listed as an adverse reaction — could be beneficial for overweight chronic obstructive pulmonary disease (COPD) patients.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives